Archive · 13 Dec 2025
Narayana Hrudayalaya: Growth and Investment Outlook
Narayana Hrudayalaya is a big healthcare company that runs hospitals in India, the Cayman Islands, and the UK.
They recently bought a group of hospitals in the UK and plan to add more beds in India by 2030.
The company is growing by offering more services and improving the types of patients they treat.
They also started insurance and clinic businesses, which are not making a profit yet but are expected to improve over time.
The company's stock has gone up a lot, and experts think it's a good time to invest because the company is growing and its stock price is not too high compared to other similar companies.
Narayana Hrudayalaya is expanding its operations in India and has acquired a UK-based hospital group, Practice Plus.
The company plans to increase its bed capacity from 5,750 to 7,600 by FY30, with an expansion cost of ₹3,000 crore.
Recent acquisitions and domestic capacity expansion are expected to drive growth over the next three to five years.
Adjacent businesses like insurance and clinics are currently impacting margins but are expected to improve as they scale up.
The company's stock has more than doubled since February 2023, and experts recommend accumulating the stock due to its growth potential and modest valuations.
- Who
- Narayana Hrudayalaya, a healthcare company with operations in India, Cayman Islands, and the UK.
- What
- The company is expanding its operations and has acquired a UK-based hospital group, Practice Plus.
- When
- The UK acquisition was completed in October 2025, with plans to expand bed capacity by FY30.
- Where
- Operations are based in India, Cayman Islands, and the UK.
- Why
- To drive growth and improve margins through expansion, acquisitions, and diversification of services.
- Current Bed Capacity
- 5,750 beds
- Target Bed Capacity by FY30
- 7,600 beds
- Expansion Cost
- ₹3,000 crore
- Revenue (FY25)
- ₹5,483 crore
- EBITDA (FY25)
- ₹1,276 crore
- Net Debt to EBIT
- 0.48 times
- UK Acquisition Cost
- ₹2,200 crore (£189 million)
- UK Target Revenue (FY24)
- £229 million
- UK Target EBITDA (FY24)
- £24 million